Approved for use through 0.3/31/2008. 0.000 6053-0033.

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMENT
U.S. Patient and Trademark Office, U.S. DEPARTMENT
U.S. Patient D.S. DEPARTMENT
U.S. DEPARTMENT
U.S. Patient D.S. DEPARTMENT
U.S. DEPART

Request	Application Numb	er 10/5	49,698-Conf. #9561
for Continued Examination (RCE) Transmittal	Filing Date	July	14, 2006
	First Named Inver	ntor Mas	anori SAKAI
Address to:	Art Unit	1792	2
Mail Stop RCE Commissioner for Patents	Examiner Name	K. T	Chen
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket N	umber 1592	2-0178PUS1
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Confinued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application flied prior to June 8, 1995, or to any design application.			
 Submission required under 37 CFR 1.114 Note: If the RCE is proper, any producity filed unentend amendments and amendments enclosed with the RCE will be natical to the order to which they were filed united applicant instructs otherwise. If applicant does not wish to have any previously filed unentened amendment(s) entered, applicant must request non-entry of such amendment(s). 			
a. X Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.			
i Consider the arguments in the Appeal Brief or Reply Brief previously filed on			
ii. X Other Amendment filed on February 13, 2008			
b. Enclosed			
i. Amendment/Reply iii. X Information Disclosure Statement (IDS)			
iiAffidavit(s)/Declaration(s) ivOther			
2. Miscellaneous			
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a			
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)			
b. Other			
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.			
a. X The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any			
overpayments to Deposit Account No. <u>02-2448</u> . I have enclosed a duplicate copy of this sheet.			
i. X RCE fee required under 37 CFR 1.17(e)			
ii. X Extension of time fee (37 CFR 1.136 and 1.17)			
iii. Other			
b. Check in the amount of \$ enclosed			
c. Payment by credit card (Form PTO-2038,enclosed)			
WARNING: Information on this form may become public. Credit and information should not be included on this form, Provide credit card information and authorization on PTO-2028			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Signature			
Name (Print/Type) Michael K. Mutter		Registration No. 29,680	